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follow-up was 8.9 years. 229 (37 %), 356 (58 %), and 
410 (66 %) fulfilled the TV0.5, TV1.3, and NoTV indo-
lent PCa criteria at RP. Discriminating between indolent 
and significant disease according to area under the curve 
(AUC) was: TV0.5: 0.658 (PRIAS), 0.523 (Klotz), 0.642 
(Hopkins), 0.685 (nomogram). TV1.3: 0.630 (PRIAS), 
0.550 (Klotz), 0.615 (Hopkins), 0.646 (nomogram). NoTV: 
0.603 (PRIAS), 0.530 (Klotz), 0.589 (Hopkins), 0.608 
(nomogram).
Conclusions The performance of a nomogram, the Johns 
Hopkins, and PRIAS rule-based criteria are comparable. 
Because the nomogram allows individual trade-offs, it 
could be a good alternative to rigid rule-based criteria.
Keywords Prostatic neoplasm · Active surveillance · 
Risk stratification · Selection for active surveillance · 
Inclusion criteria active surveillance · Nomogram
Introduction
Early detection of prostate cancer (PCa) has led to 
increased prevalence of finding indolent tumours, i.e. 
tumours that are unlikely to become symptomatic during 
life. The ability to predict indolent PCa is needed to avoid 
overtreatment [1]. Active surveillance (AS) has emerged as 
a feasible strategy to decrease the overtreatment of low-risk 
PCa. With AS, men with low-risk PCa are strictly moni-
tored over time, and if risk reclassification or disease pro-
gression occurs, they can opt for curative therapy. Hence, 
the aim of AS is to safely delay or completely avoid side 
effects of active therapy [2]. There are 16 unique world-
wide AS cohorts which all have their highly variable own 
protocols [3]. So far, published results on AS study cohorts 
worldwide show encouraging results on biochemical 
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recurrence (BCR) rates and disease-specific mortality [4]. 
Long-term effects are yet unknown. Research on how to 
improve the existing AS protocols is, however, needed as 
misclassification at diagnosis, and subsequent reclassifica-
tion after one-year repeat biopsy is not uncommon [5]. For 
example, 28 % of men within the Prostate cancer Research 
International: Active Surveillance (PRIAS) study were 
reclassified after one or more repeat biopsies [6].
Currently, all existing AS cohorts apply relatively sim-
ple combinations of inclusion criteria for patient selection 
(“rule-based selection”). More refined risk stratification 
through a nomogram may be preferable, especially in the 
light of individualised medicine and shared decision-mak-
ing (“probability-based selection”) [7]. We aimed to assess 
the performance of inclusion criteria as used in several 
prospective AS protocols in identifying indolent cancer at 
radical prostatectomy (RP) and follow-up outcomes of men 
who received immediate RP but were also suitable for AS. 
For comparison, we used a previously developed and exter-
nally validated nomogram that predicts indolent disease [8, 
9]. We hypothesise that the use of probabilistic selection by 
the use of a nomogram that incorporates multiple patient 
characteristics may be better for selection.
Materials and methods
Patients
Men included in this study were participants in the screen-
ing arm of the European Randomized study of Screening 
for Prostate Cancer (ERSPC). Data cohorts of the Swed-
ish and Dutch sections of ERSPC were combined. All men 
were diagnosed with screen-detected PCa and underwent 
RP as primary treatment. Details on both Dutch and Swed-
ish screening protocols were previously published [10, 11].
Methods
Men with T3-4, Gleason ≥7 PCa at diagnostic biopsy or an 
unknown tumour volume were excluded from this analysis, 
as well as men with positive lymph nodes or distant metas-
tases at the time of diagnosis or at the time of surgery. A 
multiple imputation model was used to fill in missing data. 
We used the first imputation of a multiple imputation pro-
cedure with the impute function in SPSS software (IBM 
Corp. Released 2012. IBM SPSS Statistics for Windows, 
version 21.0. Armonk, NY: IBM Corp). A total of 936 con-
founder values were missing, comprising 13.5 % of all val-
ues. Filling in these values through imputation allowed us 
to include the 382 (44 %) patients with any missing value 
in the analysis. All tumour characteristics were used for the 
multiple imputation.
We first assessed the frequency of indolent PCa at RP 
according to the classic definition of pT2, tumour vol-
ume <0.5 ml (TV0.5), and pathological Gleason pattern 
≤3 [12]. Men not fulfilling these criteria for indolent PCa 
(TV > 0.5 ml and/or pathological Gleason pattern >3) were 
categorised as having significant PCa.
Second, we selected men from our study cohort with 
low-risk PCa at diagnosis defined according to the PRIAS 
(T1c-T2, PSA ≤ 10 ng/ml; PSA density <0.20 ng/ml/
cc, Gleason ≤3 + 3, ≤2 positive cores), Klotz (T1b-T2b; 
PSA ≤ 10 ng/ml; Gleason ≤6), and Johns Hopkins criteria 
(T1c, PSA density <0.15 ng/ml/cc, Gleason ≤6, ≤2 posi-
tive cores, ≤50 % single core involvement). The frequen-
cies of indolent PCa at RP in these groups were studied.
Third, we explored the use of a nomogram to estimate 
risk for indolent PCa at RP [13]. We assessed the effect of 
applying various eligibility criteria for the nomogram (T1c-
T2a, PSA ≤ 20 ng/ml; Gleason ≤3 + 3, ≤50 % positive 
cores, 20 mm PCa, 40 mm benign tissue in all cores) and of 
different thresholds in the predicted chance of harbouring 
indolent PCa (referred to as Pind) on the number of men 
remaining suitable for AS at diagnosis.
The classic definition of a pathologic indolent PCa 
(pT2, TV0.5, and Gleason pattern ≤3) might be too restric-
tive and not reflecting biology well [14]. Therefore, we 
repeated steps one to three with two updated and more 
recent definitions of indolent PCa: (1) pT2, tumour volume 
<1.3 ml (TV1.3) and Gleason pattern ≤3 + 3 [14–16]; (2) 
pT2, Gleason pattern ≤3 + 3 and tumour volume no part of 
definition (NoTV) [15]. For step three, the nomogram was 
refitted twice using the original data [13], to account for the 
adjusted definitions of an indolent PCa.
Having the availability of follow-up data, we were able 
to calculate BCR after RP. The criteria proposed by Freed-
land et al. [17] were used to define BCR, i.e. one PSA value 
after RP > 0.2 ng/ml. The different sets of rule-based selec-
tion criteria and Pind cut-off points were compared using 
the Kaplan–Meier method and the log-rank test.
We finally applied decision curve analysis (DCA) [18] to 
evaluate the potential clinical usefulness of rule-based selec-
tion and probability-based selection models. We estimated a 
net benefit (NB) for the four models by summing the benefits 
(true-positive indolent PCa) and subtracting the harms (false-
positive indolent PCa).The harms were weighted by a factor 
related to the relative harm of being unjustly included on AS 
versus being directly curatively treated while suitable for AS. 
This weighting was derived from the threshold probability 
at which a patient would opt for AS. This threshold varies 
between men and urologists. Clinical practice currently uses 
a threshold probability of 50–70 % [19]. The interpretation 
of a decision curve is rather straightforward; the model with 
the highest NB at a particular threshold should be chosen 
over alternative models.
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P values (two-sided) <0.05 were considered statistically 
significant. For statistical analysis, we used the Statistical 
Package for the Social Sciences (SPSS) version 21 (IBM 
Corp. Released 2012. IBM SPSS Statistics for Windows, 
version 21.0. Armonk, NY: IBM Corp) and R version 
2.15.2 (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
Our study cohort consisted of 864 men of whom 619 had 
cT1-2, Gleason 6 disease at diagnosis and were therefore 
eligible for analyses. Median follow-up time after diag-
nosis was 8.9 years. Table 1 presents the study cohort 
characteristics at diagnosis and outcomes after RP. With 
Table 1  Study cohort 
characteristics at diagnosis 
and outcomes after radical 
prostatectomy (n = 619)
25–75p 25–75 percentile
At diagnosis
ERSPC study centre:
 The Netherlands (n,  %) 336 54
 Sweden (n,  %) 283 46
Follow-up (years) (median, 25–75p) 8.9 5.9–10.9
Age (years) (median, 25–75p) 62.9 60.1–66.2
Clinical disease stage (n,  %):
 T1c 395 64
 T2a 157 25
 T2b 37 6
 T2c 30 5
PSA (ng/ml) (median, 25–75p) 4.5 3.5–6.4
Prostate volume (cc; median, 25–75p) 35.1 28.3–45.1
PSA density (ng/ml/cc; median, 25–75p) 0.13 0.09–0.18
Total number of cores (median, 25–75p) 6 6–6
Number of positive cores (median, 25–75p) 2 1–3
Total benign tissue (mm; median, 25–75p) 67.6 56.0–78.5
Total PCa tissue (mm; median, 25–75p) 4.0 2.1–8.1
Percentage cancer per positive core (median, 25–75p) 30.5 14.7–64.3
Gleason sum:
 ≤6 619 100
Prediction indolent cancer (median, 25–75p) (n = 455 suitable for nomogram) 60 % 40–78 %
At radical prostatectomy
Tumour volume (n,  %)
 ≤0.5 cc 284 46
 >0.5 cc 335 54
 ≤1.3 cc 497 80
 >1.3 cc 122 20
Gleason sum (n,  %)
 ≤6 (no pattern 4) 468 76
 ≥7 140 24
Indolent cancer (tumour volume ≤0.5 cc, T2, Gleason ≤3 + 3 disease)
 Yes (n, %) 229 37
 No (n,  %) 390 63
Indolent cancer (tumour volume ≤1.3 cc, T2, Gleason ≤3 + 3 disease)
 Yes (n, %) 356 58
 No (n, %) 263 42
Indolent cancer (T2, Gleason ≤3 + 3 disease, no tumour volume cut-off)
 Yes (n, %) 410 66
 No (n, %) 209 34
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TV0.5 cut-off, a total of 229 (37 %) tumours at RP could 
be defined as indolent versus 390 (63 %) as significant. 
When applying the TV1.3 and NoTV indolent PCa defini-
tions, the number of indolent PCa increases to 356 (58) and 
410 (66 %), respectively. Pind could be calculated for 455 
(74 %) men meeting the nomogram inclusion criteria.
Table 2 presents the sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV) 
for all three indolent PCa definitions (TV0.5, TV1.3, 
NoTV) at RP of the rule-based selection and nomogram-
based selection approaches. The table also contains the 
effect of applying different thresholds of the nomogram 
calculated risk of harbouring indolent PCa, i.e. Pind.
The area under the curve (AUC) for the TV0.5 indolent 
definition was 0.658 for PRIAS, 0.523 for Klotz, 0.642 
for Johns Hopkins, and 0.685 for the nomogram. For the 
TV1.3 indolent definition, the AUC for PRIAS was 0.630, 
for Klotz 0.550, for Johns Hopkins 0.615, and for the refit-
ted nomogram 0.646. For the NoTV indolent definition, 
the AUC for PRIAS was 0.603, for Klotz 0.530, for Johns 
Hopkins 0.589, and for the refitted nomogram 0.608.
Table 2 furthermore presents the number of men who 
experienced BCR after RP according to the three defini-
tions of indolent disease in the different sets of rule-based 
criteria and the nomogram suitable cohort. A log-rank test 
showed that the number of men experiencing BCR do not 
differ statistically between the groups. However, the dis-
tribution of BCR over the indolent and significant group 
changes, with a rising percentage of BCR in the indolent 
group (TV0.5 = 3.4 %, TV1.3 = 4.9 %, NoTV = 6.3 %). 
We found that in ROC analysis (Appendix Fig. 1), the nom-
ogram (TV0.5) had a slightly better sensitivity-to-specific-
ity ratio than the PRIAS rules. The AUC for the nomogram 
(TV0.5) was 0.610, for PRIAS 0.584, for Klotz 0.524, for 
Johns Hopkins 0.615, for the refitted TV1.3 nomogram 
0.595, and for the refitted NoTV nomogram 0.570.
In terms of clinical usefulness, we found that in DCA 
analysis (appendix Fig. 2a–c), no large differences in NB 
were seen for threshold probabilities 50–70 %, which are 
clinically most relevant.
Discussion
In our cohort of Dutch and Swedish screen-detected PCa 
patients who all underwent initial RP, 37 % fulfilled the 
TV0.5 indolent PCa criteria at RP increasing to 58 % for 
the TV1.3 indolent PCa criteria and 66 % for the NoTV 
indolent PCa definition. More stringent rule-based AS 
inclusion criteria as well as stricter nomogram probability 
thresholds decrease the rate of misclassified tumours in a 
rather similar fashion, but both at the cost of a substantial 
number of patients no longer considered suitable for AS. 
The nomogram based on TV0.5 had slightly better sensitiv-
ity and specificity with respect to BCR outcome than the 
PRIAS and Klotz criteria. If we juxtapose the TV0.5 nom-
ogram to the Johns Hopkins criteria, the latter performed 
better but at the cost of including less patients and thereby 
curatively treating patients that might also would have been 
suitable for AS.
On the basis of a Kaplan–Meier analysis (curves not 
shown), we cannot conclude that the use of the TV0.5 
nomogram is preferred over the use of rule-based selec-
tion or vice versa. However, for BCR the TV0.5 nomogram 
outperformed the PRIAS and Klotz criteria. The TV0.5 
nomogram, however, performed slightly worse than the 
Johns Hopkins criteria. If we chose a slightly lower Pind 
and therewith allowing more men to be included on AS, 
sensitivity and specificity of the TV0.5 nomogram are still 
acceptable. This flexibility in application is a property of 
using a nomogram for selection rather than a strict set of 
rules and desirable in the light of individualised medicine 
and shared decision-making.
Because the classic definition of a pathologically indo-
lent PCa may be too restrictive [14], we also used two more 
updated definitions of an indolent PCa. When juxtapos-
ing the models, the TV0.5 nomogram (AUC 0.685) was 
slightly better in discriminating indolent from significant 
PCa than the PRIAS (AUC 0.658), Johns Hopkins (AUC 
0.642), and Klotz (AUC 0.523) criteria. This trend of the 
nomogram predicting slightly better is also seen for the 
refitted TV1.3 and NoTV nomograms.
Perfect patient selection for AS using either rule-based 
selection criteria or by applying a nomogram seems dif-
ficult at present. The AUCs illustrate that both approaches 
are currently suboptimal in differentiating indolent from 
non-indolent disease at RP in a group of men with already 
low-risk features at diagnosis. This is confirmed by the 
study of Wang et al. [20] whom in a group of 273 AS 
patients who underwent multiple biopsies and/or delayed 
RP found that nomograms designed to predict indolent 
tumours only have a modest ability to predict biopsy pro-
gression and any progression on either biopsy or surgery 
in men choosing an AS management strategy. Wang et al. 
furthermore concluded that in a subgroup of 58 men, none 
of the various nomograms were able to predict surgical 
progression at RP [20]. Since AS is incorporated into many 
guidelines (AUA, NCCN, EAU, etc.) as a viable manage-
ment strategy for men with either very low-risk or low-risk 
PCa, it is expected that more men will elect AS as their pri-
mary therapy. The optimisation of both rule-based selection 
and probability-based selection is therefore warranted.
Over the past few years, magnetic resonance imaging 
(MRI) is emerging as a tool which may be able to more 
accurately determine the risk of significant disease and 
progression of disease over time by improving sampling 
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through target biopsies [21]. MRI may therefore also help 
better select AS candidates [22]. Several studies have 
shown the additional value of MRI in an AS protocol 
[21–23]. Stamatakis et al. [22] combined MRI-based fac-
tors into a nomogram which generates a probability for 
confirmed AS candidacy. They found that three MRI-based 
factors, i.e. number of lesions, lesion suspicion, and lesion 
density, were associated with confirmatory biopsy outcome 
and reclassification. A created nomogram which uses these 
factors has promising predictive accuracy, according to 
Stamatakis et al. [22]. It could be that adding such factors 
to the currently existing rule-based selection criteria or the 
nomogram could improve sensitivity and specificity and 
therewith AS patient selection.
A first limitation of our study lies in the fact that men 
in our cohort were diagnosed with sextant biopsies. Sextant 
biopsy does not reflect current clinical practice anymore; 
nowadays, current practice relies on 8–18 core biopsies. 
Studies that applied more extended biopsy schemes argue 
that with a sextant biopsy protocol, 10–30 % of cancers 
are missed [24]. Several studies reported that when 8–12 
cores were taken, the PCa detection rate in a clinical set-
ting might increase [24, 25]. We validated the previously 
developed nomogram in multiple other populations in 
which more extended biopsy schemes were used. Results 
of these validation studies showed that the nomogram pre-
dicted indolent PCa with good discrimination, indicating 
that it can be broadly applied in contemporary urologi-
cal practice [26, 27]. In addition, we extracted correction 
factors for the adjustment of the nomogram with which 
contemporary extended biopsy schemes can be addressed 
[28]. Another limitation is that follow-up time of our study 
cohort is too short to assess mortality outcomes and relate 
these to baseline selection criteria. The lack of mortality 
outcomes was also the reason to choose BCR as an end-
point instead. Many men with BCR, however, will never 
develop metastasised disease or die from PCa [29]. Thirdly, 
patients underwent RP in different centres in either Swe-
den or the Netherlands. They were operated by different 
surgeons using different techniques for RP, which might 
influence outcomes. Finally, 247 cases included in this 
analysis were also used in the validation and construction 
of the nomogram. This may lead to an overestimated per-
formance of the nomogram and Pind. The strength of this 
study lies in the fact that all men were diagnosed with PCa 
within ERSPC (Sweden and the Netherlands), resulting in 
standardised pathological examination of biopsy specimens 
and structured data follow-up [30].
In conclusion, in our cohort of Dutch and Swedish 
screen-detected PCa patients who all underwent initial 
RP, 37 % had TV0.5 indolent PCa at RP increasing to 
58 % for the TV1.3 indolent PCa criteria and 66 % for 
the NoTV indolent PCa definition. Performance of an Se
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ERSPC-based TV0.5 nomogram and rule-based selec-
tion by the Johns Hopkins and PRIAS criteria is com-
parable. Because the nomogram allows individual trade-
offs, it could be a good alternative to applying rigid 
rule-based criteria. Furthermore, a nomogram antici-
pates on the continuous improvement of risk assess-
ment by newly emerging risk criteria, including imaging 
modalities.
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